ArticleOncology research2017

Inhibitors of PI3K/ERK1/2/p38 MAPK Show Preferential Activity Against Endocrine-Resistant Breast Cancer Cells.

Maitham A Khajah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.